Reni J. Benjamin
Stock Analyst at Citizens
(2.80)
# 1,096
Out of 5,138 analysts
13
Total ratings
27.27%
Success rate
8.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $23.63 | +35.42% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $338.29 | +17.06% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $4.67 | +71.31% | 1 | Oct 30, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $17.27 | +131.62% | 3 | Oct 20, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $8.91 | +169.36% | 2 | Oct 20, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $71.80 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $0.55 | +444.56% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $2.15 | +39.53% | 1 | Aug 18, 2025 | |
| BCAB BioAtla | Downgrades: Market Perform | n/a | $0.32 | - | 1 | Aug 13, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $22 → $10 | $6.47 | +54.56% | 1 | Aug 12, 2025 |
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $23.63
Upside: +35.42%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $338.29
Upside: +17.06%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $4.67
Upside: +71.31%
Summit Therapeutics
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $17.27
Upside: +131.62%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $8.91
Upside: +169.36%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $71.80
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.55
Upside: +444.56%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $2.15
Upside: +39.53%
BioAtla
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.32
Upside: -
Bicycle Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $6.47
Upside: +54.56%